GSK217744

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Acellular PertussisDiphtheriaHaemophilus Influenzae Type bHepatitis BPoliomyelitisTetanus

Phase 2

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

CompletedNCT01248884

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3

Start: 2010-12-09End: 2012-01-05Updated: 2018-08-20

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

CompletedNCT01453998

GlaxoSmithKlineAcellular Pertussis, Diphtheria, Haemophilus Influenzae Type b +3

Start: 2011-10-14End: 2012-11-12Updated: 2020-07-17

Related Papers

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and<i>Haemophilus influenzae</i>type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed<i>Infanrix hexa</i>

Human Vaccines & Immunotherapeutics2017-03-241 citations